Abstract
Today the term “click chemistry” is often used equivalent with the copper-catalyzed 1,3-dipolar Huisgen cycloaddition. Originally, the concept was introduced in 2001 to describe reactions fulfilling a set of criteria that are most useful for chemical syntheses in drug research. In radiopharmaceutical chemistry where short lived radioisotopes are introduced into various different substance classes for in vivo imaging of biochemical processes, the expanding field of radioactive bioconjugation has become predominant. Labeled biomolecules such as peptides, proteins and oligonucleotides generated via bioconjugation of chelators for radiometal introduction as well as novel valuable secondary precursors for 18F labeling have enriched the growing field of molecular imaging substantially. When introducing radioactive nuclides with a very short half-life into biomolecules, some of the typical criteria defined by click-chemistry are more crucial than others. Time is always the most important issue, whereas avoiding the formation of by-products that have to be removed without chromatography is of minor importance. The short-lived radionuclide 11C for example has a physical half-life of only 20 min so that the labeling procedure cannot exceed 40-60 minutes (2-3 half-lifes). In this contribution, we outline reactions and molecules which meet the requirements of click chemistry reactions and are suitable for radiosyntheses of short lived SPECT (99mTc: t1/2 = 6 h, 111In: t1/2 = 2.81 d) and PET (11C: t1/2 = 20.3 min to 64Cu: t1/2 = 12.7 h) radiotracers for in vivo imaging of biological processes and review the contributions in the field of radiochemical “click-reactions” - 1,3-dipolar Huisgen cycloadditions and beyond.
Keywords: Click chemistry, bioconjugation, radionuclides, in vivo imaging
Current Medicinal Chemistry
Title: Click-Chemistry Reactions in Radiopharmaceutical Chemistry: Fast & Easy Introduction of Radiolabels into Biomolecules for In Vivo Imaging
Volume: 17 Issue: 11
Author(s): C. Wangler, R. Schirrmacher, P. Bartenstein and B. Wangler
Affiliation:
Keywords: Click chemistry, bioconjugation, radionuclides, in vivo imaging
Abstract: Today the term “click chemistry” is often used equivalent with the copper-catalyzed 1,3-dipolar Huisgen cycloaddition. Originally, the concept was introduced in 2001 to describe reactions fulfilling a set of criteria that are most useful for chemical syntheses in drug research. In radiopharmaceutical chemistry where short lived radioisotopes are introduced into various different substance classes for in vivo imaging of biochemical processes, the expanding field of radioactive bioconjugation has become predominant. Labeled biomolecules such as peptides, proteins and oligonucleotides generated via bioconjugation of chelators for radiometal introduction as well as novel valuable secondary precursors for 18F labeling have enriched the growing field of molecular imaging substantially. When introducing radioactive nuclides with a very short half-life into biomolecules, some of the typical criteria defined by click-chemistry are more crucial than others. Time is always the most important issue, whereas avoiding the formation of by-products that have to be removed without chromatography is of minor importance. The short-lived radionuclide 11C for example has a physical half-life of only 20 min so that the labeling procedure cannot exceed 40-60 minutes (2-3 half-lifes). In this contribution, we outline reactions and molecules which meet the requirements of click chemistry reactions and are suitable for radiosyntheses of short lived SPECT (99mTc: t1/2 = 6 h, 111In: t1/2 = 2.81 d) and PET (11C: t1/2 = 20.3 min to 64Cu: t1/2 = 12.7 h) radiotracers for in vivo imaging of biological processes and review the contributions in the field of radiochemical “click-reactions” - 1,3-dipolar Huisgen cycloadditions and beyond.
Export Options
About this article
Cite this article as:
Wangler C., Schirrmacher R., Bartenstein P. and Wangler B., Click-Chemistry Reactions in Radiopharmaceutical Chemistry: Fast & Easy Introduction of Radiolabels into Biomolecules for In Vivo Imaging, Current Medicinal Chemistry 2010; 17 (11) . https://dx.doi.org/10.2174/092986710790820615
DOI https://dx.doi.org/10.2174/092986710790820615 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HDL Therapy: Two Kinds of Right?
Current Pharmaceutical Design Fibrinolytic Factors in Liver Fibrosis
Current Pharmaceutical Biotechnology Micro-RNA in Disease and Gene Therapy
Current Drug Discovery Technologies In Vitro and In Vivo Investigations into the Carbene Gold Chloride and Thioglucoside Anticancer Drug Candidates NHC-AuCl and NHC-AuSR
Letters in Drug Design & Discovery Cisplatin Properties in a Nanobiotechnological Approach to Cancer: A Mini-Review
Current Cancer Drug Targets Novel Neuroendocrine and Metabolic Mechanism Provides the Patented Platform for Important Rejuvenation Therapies: Targeted Therapy of Telomere Attrition and Lifestyle Changes of Telomerase Activity with the Timing of Neuron-Specific Imidazole-Containing Dipeptide-Dominant Pharmaconutrition Provision
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Lung Cancer May Increase Serum Procalcitonin Level
Infectious Disorders - Drug Targets Recent Advances on Patents in Poly(Ethylene Glycol)-Based Drug Delivery
Recent Patents on Drug Delivery & Formulation NK-1 Receptor Antagonists: A New Generation of Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Genistein: A Boon for Mitigating Ischemic Stroke
Current Topics in Medicinal Chemistry Steroidal Cardiac Na<sup>+</sup>/K<sup>+</sup> ATPase Inhibitors Exhibit Strong Anti-Cancer Potential <i>in vitro</i> and in Prostate and Lung Cancer Xenografts <i>in vivo</i>
Anti-Cancer Agents in Medicinal Chemistry Angiogenin as a Molecular Target for the Treatment of Prostate Cancer
Current Cancer Therapy Reviews Overview on Anticancer Drug Design and Development
Current Medicinal Chemistry Repressing the Activity of Protein Kinase CK2 Releases Mitochondria-Mediated Apoptosis in Cancer Cells
Current Drug Targets The Role of the Calcium-Sensing Receptor in Bone Biology and Pathophysiology
Current Pharmaceutical Biotechnology The Therapeutic Potential of ADAM15
Current Pharmaceutical Design De Novo Malignancies After Organ Transplantation: Focus on Viral Infections
Current Molecular Medicine Targeting Hypoxia for Sensitization of Tumors to Radio- and Chemotherapy
Current Cancer Drug Targets Cell Compatibility of an Eposimal Vector Mediated by the Characteristic Motifs of Matrix Attachment Regions
Current Gene Therapy Withdrawal Notice: Role, Significance and Association of microRNA-10a/b in Physiology of Cancer
MicroRNA